Press release · bioxconomy.com
Jupiter Neurosciences licenses MDMA asset
Jupiter Neurosciences has signed a licensing agreement with PharmAla Biotech Holdings for exclusive US rights to ALA-002. The deal marks Jupiter’s expansion from a single-asset company centred on its Parkinson’s disease.
